The possibility of a direct mitochondrial action of Na + /H + exchanger-1 (NHE-1) inhibitors decreasing reactive oxygen species (ROS) production was assess in cat myocardium. Angiotensin II and endothelin-1 induced an NADPH oxidase- 
INTRODUCTION
The myocardial Na + /H + exchanger-1 (NHE-1) plays a critical role in intracellular pH regulation during physiological and pathological processes.
NHE-1 catalyzes the electroneutral exchange of intracellular protons for extracellular Na + by a secondary active process that takes energy from the transmembrane Na + gradient. Although NHE-1 is relatively quiescent under basal conditions, it is activated in many pathologic conditions, like ischemia/reperfusion injury and cardiac overload, and after pharmacological interventions like angiotensin II (Ang II), endothelin (ET), and α-adrenergic stimulation, which exert their effect through the activation of several kinases [for a review, see (5)].
NHE-1 hyperactivity leads to intracellular accumulation of Na + , which induces intracellular Ca 2+ overload via the Na + /Ca 2+ exchanger (NCX) (14). One of the mechanisms by which NHE-1 inhibitors protect against ischemia/reperfusion injury may be the prevention of the intracellular accumulation of Na + and Ca 2+ that occurs because of NHE-1 hyperactivity (4, 26); this mechanism may also explain the protective effects of NHE-1 inhibitors in cardiac hypertrophy and failure (6, 12) and the mitochondrial death pathway (51). An increase in reactive oxygen species (ROS) production has been associated with the cardiovascular pathologies that NHE-1 inhibition affects beneficially (3, 8, 15, 22, 45, 49, 55) . Interestingly, there are several reports that suggest a link between ROS and NHE-1 activation (41, 46, 50) . Moreover, the experiments performed by Wei et al. (54) indicate that ROS induce activation of the MEK-ERK1/2-p90 RSK pathway, which increases NHE-1 activity via a phosphorylation process. In line with this hypothesis are the results reported by Ruiz-Meana et al. (47) suggesting that cariporide may inhibit the mitochondrial NHE (MNHE) delaying mitochondrial matrix acidification and ATP depletion.
Therefore, downregulation of mitochondrial ROS induced by NHE-1 inhibitors could exert additional beneficial effects to those derived from the inhibition of the sarcolemmal NHE-1. In the present study we test the hypothesis that NHE-1
inhibitors have a mitochondrial effect leading to a decrease in ROS production. Preparation of cardiac slices: Cardiac tissue slices from the left ventricle (1 x 5 mm) were obtained and kept at 4 °C until assayed as previously described (10). glibenclamide, rotenone, and NHE-1 inhibitors). At the end of the incubation myocytes were homogenized in lysis buffer and the relative amounts of Pp90 RSK and P-ERK1/2 were determined by Western blot as previously described (10). Total p90 RSK and ERK-2 as a loading control were assayed.
Methods

All procedures followed during this investigation conform to the
Isolation of cardiac mitochondria:
Hearts were homogenized in ice-cold buffer containing (in mmol/L) 250 sucrose, 10 Tris·HCl, 1 PMFS, pH 7.4. The homogenate was centrifuged at 1000×g for 3 min at 2 °C, and then the supernatant was centrifuged at 10000×g for 10 min at 2 °C. The resulting pellets were used for determination of mitochondrial swelling.
Mitochondrial swelling determination:
The detection of changes in 90° light scattering in mitochondrial suspensions is a convenient method to study were assessed by one-way ANOVA followed by Student-Newman-Keuls test. P < 0.05 was considered significant. 
RESULTS
Ang II induces an NADPH oxidase (NOX)-dependent increase in ROS production
Mitochondria emerges as the main source of the O 2 -detected
The mitochondrial electron transport chain, especially at complex I and complex III, probably represents the major source of O 2 -production in cardiac myocytes. In vascular smooth muscle cells, mK ATP channels have been implicated in Ang II-induced ROS production (33) . To determine whether in the myocardium the opening of these channels is involved in the mitochondrial production of ROS induced by Ang II, cardiac slices were exposed to 5-HD (100 μmol/L) and glibenclamide (50 μmol/L), a specific and a non-selective mK ATP channel blocker, respectively. The NOX-dependent increase in O 2 -production induced by Ang II was canceled by both 5-HD and glibenclamide ( Figure 2D , Ang II did not increase O 2 -production in the presence of rotenone, indicating that mitochondrial electron transport chain complex I was responsible for the increased oxidative stress. We identified no effect of rotenone on O 2 -basal production (Fig. 2D ). The experiment illustrated in Figure   2E shows that CsA, a potent inhibitor of MPTP opening, also prevented the rise in O 2 -production induced by 1 nmol/L Ang II, suggesting that MPTP opening is a necessary step for the NOX-induced mitochondrial release of ROS, as previously proposed (9). Therefore, Ang II, at the concentration used in the present experiments, appears to induce a NOX-dependent mitochondrial release of O 2 -, a find in agreement with recent reports (57).
NHE-1 inhibitors prevent ROS release by directly targeting mitochondria
Several reports from different authors, including our group, have suggested an interaction between mitochondria and NHE-1 inhibitors (22, 27, 28, 47, 51); in addition, the prevention of oxidative stress appears to be beneficial in most of the cardiovascular pathologies in which NHE-1 inhibitors are effective (11, 15, 22, 35, 37, 38) . Therefore, we analyzed the effect of three different NHE-1 blockers on the increased O 2 -production induced by Ang II.
As shown in Figure 3A , administration of each of the NHE-1 blockers examined-cariporide (10 μmol/L), BIIB723 (10 μmol/L), and EMD87580 (5 μmol/L)-prevented the Ang II-induced rise in O 2 -production. None of these compounds had a detectable effect on O 2 -basal production (inset of Fig. 3A) .
However, to rule out the possibility that these compounds act as O 2 -scavengers, we induced O 2 -production in vitro by PMS and NADH in a range that included the values obtained with 1-100 nmol/L Ang II. Under these experimental conditions, we measured the chemiluminescence signal in the absence and presence of each of the above mentioned NHE-1 inhibitors. Figure 3B shows that there was no detectable change in O 2 -production when the NHE-1 inhibitors were added to the medium. Therefore, we can assume that these inhibitors did not exert a scavenger effect.
Using the same experimental conditions as in the Ang II experiments, we examined the effect on myocardial O 2 -production of another G q protein coupled receptor agonist, ET-1 (5 nmol/L), which is known to activate NOX (21, 36). We obtained results that were essentially the same as those elicited by Ang II. ET-1 induced a NOX-dependent mitochondrial release of O 2 -that was prevented by the non-selective ET receptor blocker TAK044 (5 μmol/L), the ET A receptor blocker BQ123 (10 μmol/L), the NOX inhibitor apocynin (300 μmol/L), the mK ATP channel blockers 5-HD (100 μmol/L) and glibenclamide (50 μmol/L), and the NHE-1 inhibitor cariporide (10 μmol/L), as it is shown in Figure 4A .
When we stimulated mitochondrial O 2 -production by directly inducing mK ATP channel opening with diazoxide, we detected a dose-dependent rise in lucigenin chemiluminescence signal in cardiac slices (Fig. 4B) . The increase in the chemiluminescence signal observed with 100 μmol/L diazoxide was of the same order of magnitude as that induced by 1 nmol/L Ang II and 5 nmol/L ET-1; in addition, it was prevented by the mK ATP channel blocker 5-HD, by the NHE-1 inhibitor cariporide, and by CsA (Fig. 4C) . These results are similar to those obtained by Kimura et al. (33) in rat vascular smooth muscle cells, in which they measured the effects of Ang II and diazoxide on ROS production. 
Cariporide decreases Ca
The inhibition of mitochondrial ROS release prevents ERK1/2 and p90
RSK phosphorylation
There is evidence that ROS can act as signaling molecules to regulate cellular functions by activating protein kinase cascades (46, 48, 50) . According to our data, in which the NHE-1 inhibitors blunted the Ang II-induced increase in ROS formation, the prevention of this kinase activation should be expected when Ang II is administered in the presence of the NHE-1 inhibitors. The data presented in Figure 6 show a significant increase in ERK1/2 and p90 can also induce damage to the heart (32). This matter is out of the scope of the present study, but similarly to what was proposed for the MPTP opening, the effects may be related to the duration, timing, location, and extent of ROS release. Figure 7 schematizes the two-step mechanism previously proposed for the increase of ROS formation induced by a G-coupled receptor agonist and the possible mechanism involved in its reduction induced by NHE-1 inhibitors.
In brief, we report here a direct mitochondrial "anti-ROS" action of NHE-1 inhibitors detected in cardiac slices and isolated mitochondria. Although we could not dissect the precise site of action of the inhibitors on the mitochondria, the knowledge of these effects opens new avenues of research and helps illuminate the reasons for some of the contradictory results. 
